Clotting Disorders

Clotting Disorders

A collection of features and news articles published in ASH Clinical News related to clotting disorders.

Alice Ma, MD

Summertime Blues

At the time of writing this column, the calendar has just turned to August and another July has come and gone. There’s plenty of...

FDA Approves Lusutrombopag for Thrombocytopenia in Liver Disease

The U.S. Food and Drug Administration (FDA) has approved lusutrombopag for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled...
WIB_icon

Study Finds Thromboembolism Is a Frequent Complication of ALL Treatment

Adolescents and adults with acute lymphocytic leukemia (ALL) are at a “markedly” increased risk for developing thromboembolism (TE), even when treated according to the...
WIB_icon

Insights From a Pyruvate Kinase Deficiency Registry: Broad Spectrum of Severity, Broad Role for...

No guidelines exist for the diagnosis, management, and monitoring of patients with red cell pyruvate kinase (PK) deficiency – the most common glycolytic defect...

FDA Examining Patient Deaths Associated With Extracorporeal Photopheresis Treatment

The FDA published a letter to health-care providers noting that the CELLEX® Photopheresis System is under review following reports of venous thromboembolism (VTE), including...

Aspirin as Effective as Rivaroxaban for Preventing VTE After Total Hip or Knee Arthroplasty

Standard aspirin is as effective as the newer, direct oral anticoagulant (DOAC) rivaroxaban for preventing venous thromboembolism (VTE) in patients who have undergone total...

A Preview of ASH’s Venous Thromboembolism Clinical Practice Guidelines

In November 2015, the American Society of Hematology (ASH) and the McMaster University GRADE Center announced a collaboration to develop clinical practice guidelines on...

Is Oral Edoxaban an Alternative to Standard Anticoagulation in Cancer-Associated VTE?

Low-molecular-weight heparin is the standard, guideline-recommended anticoagulation therapy for patients with cancer and venous thromboembolism (VTE), but the daily subcutaneous injections can be burdensome....

Can Electronic Alerts Improve VTE Prophylaxis Delivery?

The use of thromboprophylaxis among hospitalized patients at risk for a venous thromboembolism (VTE) – a major complication of hospitalization – remains inconsistent. Both...

FDA Approves Lower Dose of Rivaroxaban for Recurrent VTE

The U.S. Food and Drug Administration approved 10 mg once-daily dosing for rivaroxaban to prevent recurrent venous thromboembolism (VTE) after at least six months...
Advertisement

Current Issue

August 2018, Volume 4, Issue 10

This issue features a look at direct-to-consumer pharmaceutical advertising, advice to graduating hematologists, and more.